Dr. He Huang: Focusing on the Rise and Challenges of Cellular Immunotherapy | The 8th CSCO Hematology Academic Conference

Dr. He Huang: Focusing on the Rise and Challenges of Cellular Immunotherapy | The 8th CSCO Hematology Academic Conference

To further enhance the diagnosis and treatment of leukemia and lymphoma in China, the 8th Hematology Academic Conference, jointly organized by the Chinese Society of Clinical Oncology (CSCO), CSCO Leukemia Expert Committee, and Lymphoma Expert Committee, and co-hosted by Harbin Institute of Hematology and Oncology and Peking University Cancer Hospital, was held grandly in Harbin from July 26 to 28. The conference aimed to provide an important platform for in-depth learning and extensive exchange among experts and scholars in the field of hematological tumors. On this occasion, "Oncology Frontier - Hematology Frontier" specially invited Dr. He Huang from The First Affiliated Hospital , Zhejiang University School of Medicine to discuss the frontier topic of cellular immunotherapy.
Dr. Erlie Jiang: Exploring Stem Cell Transplantation Strategies for Adult Acute Lymphoblastic Leukemia |The 8th CSCO Hematology Academic Conference

Dr. Erlie Jiang: Exploring Stem Cell Transplantation Strategies for Adult Acute Lymphoblastic Leukemia |The 8th CSCO Hematology Academic Conference

To further enhance the diagnosis and treatment of leukemia and lymphoma in China, the 8th Hematology Academic Conference, jointly organized by the Chinese Society of Clinical Oncology (CSCO), CSCO Leukemia Expert Committee, and CSCO Lymphoma Expert Committee, and co-hosted by Harbin Institute of Hematology and Oncology and Peking University Cancer Hospital, was grandly held in Harbin from July 26 to 28, 2024. On this occasion, "Oncology Frontier - Hematology Frontier" invited Dr. Erlie Jiang from the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, to discuss the frontier topic of hematopoietic stem cell transplantation (HSCT).
Dr. Jun Ma: Gathering Global Experts to Discuss Cutting-Edge Advances and Core Concepts | The 8th CSCO Annual Hematology Conference

Dr. Jun Ma: Gathering Global Experts to Discuss Cutting-Edge Advances and Core Concepts | The 8th CSCO Annual Hematology Conference

In the sweltering summer, we gather in Ice City. The “8th Annual Hematology Conference” organized by the Chinese Society of Clinical Oncology (CSCO), the CSCO Leukemia Expert Committee, and the CSCO Lymphoma Expert Committee, and hosted by the Harbin Institute of Hematology and Oncology and Peking University Cancer Hospital, was grandly held in Harbin from July 26 to 28, 2024. Renowned experts and scholars from both domestic and international arenas came together to present and discuss research in leukemia, lymphoma, and myeloma, as well as address hot topics in clinical practice. On the first day of the conference, we were honored to interview Dr. Jun Ma, the conference chairman and director of the Harbin Institute of Hematology and Oncology, to share the highlights and core concepts of this year’s event.
Dr. Jing Sun: SYK Inhibitors Set Sail at EHA – Solepinib’s Dual Mechanism Offers New Hope for ITP Treatment

Dr. Jing Sun: SYK Inhibitors Set Sail at EHA – Solepinib’s Dual Mechanism Offers New Hope for ITP Treatment

The annual meeting of the European Hematology Association (EHA) is an international conference in the field of hematology, bringing together numerous experts and scholars from around the world to share and delve into innovative ideas and research progress, promoting continuous development in the field of hematology. This year, the research achievements of spleen tyrosine kinase (SYK) inhibitors attracted significant attention. HMPL-523 (Solepinib), the first SYK inhibitor from China to apply for market approval (*as of the press date), presented multiple research results at the EHA conference. In this issue, "Oncology Frontier - Hematology Frontier" invited Dr. Jing Sun from the Department of Hematology at Nanfang Hospital, Southern Medical University, to provide an in-depth interpretation of the ESLIM-01 study (NCT05029635) on Solepinib in the treatment of primary immune thrombocytopenia (ITP), aiming to offer clinical practice insights.
New Staging of Hepatocellular Carcinoma Using Radiomics Published in eClinical Medicine by Liver Disease Center of Nanfang Hospital

New Staging of Hepatocellular Carcinoma Using Radiomics Published in eClinical Medicine by Liver Disease Center of Nanfang Hospital

Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related deaths worldwide. Early detection, diagnosis, and intervention can significantly reduce mortality rates. HCC development is driven by a series of complex processes, often starting from hepatitis and cirrhosis. During this progression, subtle changes in cellular gene expression, major shifts in molecular signaling pathways, and significant changes in tissue structure and organ function collectively accelerate HCC formation and progression, leading to changes in liver imaging. Researchers have used radiomics and deep learning technologies to timely and accurately identify and intervene in the formation stage of HCC, named the Transition Stage, potentially revolutionizing early prevention and intervention strategies for HCC.
Hepatology | Long-term Prognosis and HCC Risk Stratification in Compensated Advanced Chronic Liver Disease Post-HCV Clearance

Hepatology | Long-term Prognosis and HCC Risk Stratification in Compensated Advanced Chronic Liver Disease Post-HCV Clearance

Chronic hepatitis C virus (HCV) infection is a major cause of cirrhosis and hepatocellular carcinoma (HCC). In recent years, the treatment of HCV infection has undergone revolutionary changes, transforming chronic HCV infection into a curable disease. Although direct-acting antiviral (DAA) therapy can effectively clear HCV, improve liver fibrosis, and reduce the risk of HCC, certain factors such as age, liver fibrosis, metabolic diseases, genetic factors, and treatment regimens still put some patients at high risk for HCC even after HCV clearance. A recent study on the long-term prognosis of patients with advanced chronic liver disease post-HCV cure reveals that these patients continue to face risks of hepatic decompensation and HCC. This finding is crucial for developing long-term management strategies for cured HCV patients.
BOC/BOA 2024 | Professor Tiejun Gong: Interpretation of Three Major Studies in Hematologic Oncology

BOC/BOA 2024 | Professor Tiejun Gong: Interpretation of Three Major Studies in Hematologic Oncology

From July 5th to 7th, the highly anticipated 2024 Annual Progress Seminar in Clinical Oncology in China (BOC) and Best of ASCO 2024 China were grandly held in Guangzhou. Based on the actual situation of cancer incidence in China, the conference specially invited authoritative experts in the field of oncology and carefully selected outstanding papers from the 2024 ASCO conference for comprehensive and in-depth interpretation. During the conference, "Oncology Frontier - Hematology Frontier" conducted an exclusive interview with Professor Tiejun Gong from the Harbin Institute of Hematology and Oncology. He shared his profound insights and unique academic perspectives on major studies presented at ASCO this year, the progress of the novel CD3 x CD19 IgG4 bispecific antibody CN201, and the overall status and future prospects of hematologic oncology treatment in China.
BOC/BOA 2024 | Professor Jun Ma: Showcasing Oncology Frontiers and Uniting the Anti-Cancer Front for an Innovative Future

BOC/BOA 2024 | Professor Jun Ma: Showcasing Oncology Frontiers and Uniting the Anti-Cancer Front for an Innovative Future

From July 5th to 7th, 2024, the Annual Progress Seminar in Clinical Oncology in China (BOC) and Best of ASCO® 2024 China (BOC/BOA) were grandly held in Guangzhou. In the wake of ASCO's profound impact, BOC/BOA gathered cutting-edge advancements from home and abroad, showcasing China's innovative capabilities. With a special focus on hematologic malignancies and oncology innovation, the event resonated with global progress. "Oncology Frontier - Hematology Frontier" interviewed one of CSCO's founders, Professor Jun Ma, Director of the Harbin Institute of Hematology and Oncology, to highlight the significance of BOC/BOA.
ASCO Hot Review丨Dr. Shanshan Wang: Multiple Prostate Cancer Studies Announced, Further Improving Patient Survival and Quality of Life

ASCO Hot Review丨Dr. Shanshan Wang: Multiple Prostate Cancer Studies Announced, Further Improving Patient Survival and Quality of Life

Prostate cancer incidence rates in China are currently surging, with high mortality rates and a significant disease burden. Various studies have actively explored ways to improve patients' quality of life, and evidence for the combination of PARP inhibitors with NHA and immunotherapy has brought new options and hope for prostate cancer treatment. This year's ASCO annual meeting announced multiple latest advancements in prostate cancer research. "Oncology Frontier" invited Dr. Shanshan Wang from Fudan University Shanghai Cancer Center to summarize and share these findings.